**REFERENCES**

1. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res.* 2014;74:2913–2921.

2. Hruban RH, Canto MI, Goggins M, et al. Update on familial pancreatic cancer. *Adv Surg.* 2010;44:293–311.

3. Scientific framework for recalcitrant cancers 2013. In: *One Hundred Twelfth Congress of the United States of America.*Washington, DC: 2012. HR 4310–13:1083. Available at: [http://www.gpo.gov/fdsys/pkg/BILLSHYPERLINK "http://www.gpo.gov/fdsys/pkg/BILLS-112hr4310enr/pdf/BILLS-112hr4310enr.pdf"-112hr4310enr/pdf/BILLS-112hr4310enr.pdf](http://www.gpo.gov/fdsys/pkg/BILLS-112hr4310enr/pdf/BILLS-112hr4310enr.pdf). Accessed April 16, 2015.

4. SEER. Fast Facts: Pancreatic Cancer. Available at: [http://seer.cancer.gov/HYPERLINK "http://seer.cancer.gov/statfacts/html/pancreas.html"statfacts/html/pancreas.html](http://seer.cancer.gov/statfacts/html/pancreas.html). Accessed April 16, 2015.

5. Edwards BK, Noone AM, Mariotto AB, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. *Cancer.* 2014;120:1290–1314.

6. Katz MH, Hwang R, Fleming JB, et al. Tumor-node-metastasis staging of pancreatic adenocarcinoma. *Cancer.* 2008;58:111–125.

7. Ishikawa O, Ohigashi H, Imaoka S, et al. Minute carcinoma of the pancreas measuring 1 cm or less in diameter—collective review of Japanese case reports. *Hepatogastroenterology.* 1999;46:8–15.

8. Tsuchiya R, Noda T, Harada N, et al. Collective review of small carcinomas of the pancreas. *Ann Surg.* 1986;203:77–81.

9. Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and management. *World J Gastroenterol.* 2014;20:10740–10751.

10. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. *J Gastrointest Surg.* 2000;4:567–579.

11. Andea A, Sarkar F, Adsay VN. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. *Mod Pathol.* 2003;16:996–1006.

12. Luttges J, Reinecke-Luthge A, Mollmann B, et al. Duct changes and K-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution. *Virchows Arch.* 1999;435:461–468.

13. Tada M, Ohashi M, Shiratori Y, et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. *Gastroenterology.* 1996;110:227–231.

14. Maitra A, Adsay NV, Argani P, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. *Mod Pathol.* 2003;16:902–912.

15. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. *Nature.* 2010;467:1114–1117.

16. Pelaez-Luna M, Takahashi N, Fletcher JG, et al. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. *Am J Gastroenterol.* 2007;102:2157–2163.

17. Gangi S, Fletcher JG, Nathan MA, et al. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. *Am J Roentgenol.* 2004;182:897–903.

18. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer–associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. *Gastroenterology.* 2008;134:95–101.

19. Gobbi PG, Bergonzi M, Comelli M, et al. The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer. *Cancer Epidemiol.* 2013;37:186–190.

20. Sohal DP, Walsh RM, Ramanathan RK, et al. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. *J Natl Cancer Inst.* 2014;106:dju011.

21. Mayo SC, Nathan H, Cameron JL, et al. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. *Cancer.* 2012;118:2674–2681.

22. Crippa S, Salvia R, Warshaw AL, et al. Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. *Ann Surg.* 2008;247:571–579.

23. Waters JA, Schnelldorfer T, Aguilar-Saavedra JR, et al. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage. *J Am Coll Surg.* 2011;213:

275–283.

24. Salvia R, Fernandez-del Castillo C, Bassi C, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. *Ann Surg.* 2004;239:678–685 discussion 677–685.

25. Gebhardt C, Meyer W, Reichel M, et al. Prognostic factors in the operative treatment of ductal pancreatic carcinoma. *Langenbecks Arch Surg.* 2000;385:14–20.

26. Yamaguchi K, Mizumoto K, Noshiro H, et al. Pancreatic carcinoma: < or = 2 cm versus > 2 cm in size. *Int Surg.* 1999;84:213–219.

27. Fortner JG, Klimstra DS, Senie RT, et al. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. *Ann Surg.* 1996;223:147–153.

28. Petrek JA, Sandberg WA, Bean PK, et al. Can survival in pancreatic adenocarcinoma be predicted by primary size or stage? *Am Surg.* 1985;51:42–46.

29. Tsunoda T, Yamamoto Y, Kimoto M, et al. Staging and treatment for patients with pancreatic cancer. How small is an early pancreatic cancer? *J Hepatobiliary Pancreat Surg.* 1998;5:128–132.

30. Chari ST. Detecting early pancreatic cancer: problems and prospects. *Semin Oncol.* 2007;34:284–294.

31. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. *Clin Gastroenterol Hepatol.* 2004;2:606–621.

32. Goggins M, Canto M, Hruban R. Can we screen high-risk individuals to detect early pancreatic carcinoma? *J Surg Oncol.* 2000;74:243–248.

33. Brentnall TA, Bronner MP, Byrd DR, et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. *Ann Intern Med.* 1999;131:247–255.

34. Seufferlein T, Bachet JB, van Cutsem E, et al. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2012;23(suppl 7):vii33–vii40.

35. Dewitt J, Devereaux BM, Lehman GA, et al. Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review. *Clin Gastroenterol Hepatol.* 2006;4:717–725 quiz 664.

36. van Geenen EJ, Smits MM, Schreuder TC, et al. Smoking is related to pancreatic fibrosis in humans. *Am J Gastroenterol.* 2011;106:1161–1166 quiz 1167.

37. Detlefsen S, Sipos B, Feyerabend B, et al. Pancreatic fibrosis associated with age and ductal papillary hyperplasia. *Virchows Arch.* 2005;447:800–805.

38. Pitchumoni CS, Glasser M, Saran RM, et al. Pancreatic fibrosis in chronic alcoholics and nonalcoholics without clinical pancreatitis. *Am J Gastroenterol.* 1984;79:382–388.

39. Eshleman JR, Norris AL, Sadakari Y, et al. KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound. *Clin Gastroenterol Hepatol.* 2015;13:963–969.e4.

40. Duffy MJ, Sturgeon C, Lamerz R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. *Ann Oncol.* 2010;21:441–447.

41. Gui JC, Yan WL, Liu XD. CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis. *Clin Exp Med.* 2014;14:225–233.

42. Poruk KE, Firpo MA, Adler DG, et al. Screening for pancreatic cancer: why, how, and who? *Ann Surg.* 2013;257:17–26.

43. Templeton AW, Brentnall TA. Screening and surgical outcomes of familial pancreatic cancer. *Surg Clin North Am.* 2013;93:629–645.

44. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. *Cancer Res.* 2004;64:2634–2638.

45. Permert J, Ihse I, Jorfeldt L, et al. Pancreatic cancer is associated with impaired glucose metabolism. *Eur J Surg.* 1993;159:101–107.

46. Permert J, Adrian TE, Jacobsson P, et al. Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor? *Am J Surg.* 1993;165:61–66.

47. Permert J, Larsson J, Ihse I, et al. Diagnosis of pancreatic cancer. Alteration of glucose metabolism. *Int J Pancreatol.* 1991;9:113–117.

48. Cersosimo E, Pisters PW, Pesola G, et al. Insulin secretion and action in patients with pancreatic cancer. *Cancer.* 1991;67:486–493.

49. Pannala R, Leirness JB, Bamlet WR, et al. Very high prevalence of new-onset diabetes and impaired fasting glucose in pancreatic cancer—results of a case-control study. *Gastroenterology.* 2007;132:A118.

50. Chari ST, Klee GG, Miller LJ, et al. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. *Gastroenterology.* 2001;121:640–645.

51. Chari ST, Leibson CL, Rabe KG, et al. Probability of pancreatic cancer following diabetes: a population-based study. *Gastroenterology.* 2005;129:504–511.

52. Damiano J, Bordier L, Le Berre JP, et al. Should pancreas imaging be recommended in patients over 50 years when diabetes is discovered because of acute symptoms? *Diabetes Metab.* 2004;30:203–207.

53. Ogawa Y, Tanaka M, Inoue K, et al. A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. *Cancer.* 2002;94:2344–2349.

54. Lynch SM, Vrieling A, Lubin JH, et al. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. *Am J Epidemiol.* 2009;170:403–413.

55. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. *Nat Rev Gastroenterol Hepatol.* 2009;6:699–708.

56. Raimondi S, Lowenfels AB, Morselli-Labate AM, et al. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. *Best Pract Res Clin Gastroenterol.* 2010;24:349–358.

57. Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. *Eur J Cancer.* 2011;47:1928–1937.

58. Pannala R, Basu A, Petersen GM, et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. *Lancet Oncol.* 2009;10:88–95.

59. Singh S, Singh PP, Singh AG, et al. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. *Am J Gastroenterol.* 2013;108:510–519 quiz 520.

60. Risch HA, Lu L, Wang J, et al. ABO blood group and risk of pancreatic cancer: a study in Shanghai and meta-analysis. *Am J Epidemiol.* 2013;177:1326–1337.

61. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. *J Natl Cancer Inst.* 2001;93:1054–1061.

62. Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. *Gastroenterology.* 2012;142:248–256; quiz e225-246.

63. Raimondo M, Yab TC, Mahoney DW, et al. 781 sensitive DNA marker panel for detection of pancreatic cancer by assay in pancreatic juice. *Gastroenterology.* 2014;146:S-132.

64. Raimondo M, Yab TC, Mahoney DW, et al. 487 methylated DNA markers in pancreatic juice discriminate pancreatic cancer from chronic pancreatitis and normal controls. *Gastroenterology.* 2013;144:S-90.

65. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med.* 2014;370:1287–1297.

66. Lidgard GP, Domanico MJ, Bruinsma JJ, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. *Clin Gastroenterol Hepatol.* 2013;11:1313–1318.

67. Kisiel JB, Yab TC, Taylor WR, et al. Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates. *Cancer.* 2012;118:2623–2631.

68. Hwang C, Kumar S, Yab TC, et al. Noninvasive detection of intraductal papillary mucinous neoplasm (IPMN) and early stage cancer of the pancreas with stool DNA testing. *Gastroenterology.* 2011;140:S-678.

69. Strauss BB, Yab TC, O HM, et al. Fecal recovery of ingested cellular DNA: implications for noninvasive detection of upper gastrointestinal neoplasms. *Gastroenterology.* 2014;146:S-323–S-324.

70. Kisiel JB, Taylor WR, Yab TC, et al. 769 novel methylated DNA markers predict site of gastrointestinal cancer. *Gastroenterology.* 2013;144 (Suppl 1):S84.

71. Denny P, Hagen FK, Hardt M, et al. The proteomes of human parotid and submandibular/sublingual gland salivas collected as the ductal secretions. *J Proteome Res.* 2008;7:1994–2006.

72. Yan W, Apweiler R, Balgley BM, et al. Systematic comparison of the human saliva and plasma proteomes. *Proteomics Clin Appl.* 2009;3:116–134.

73. Hu Z, Zimmermann BG, Zhou H, et al. Exon-level expression profiling: a comprehensive transcriptome analysis of oral fluids. *Clin Chem.* 2008;54:824–832.

74. Li Y, Elashoff D, Oh M, et al. Serum circulating human mRNA profiling and its utility for oral cancer detection. *J Clin Oncol.* 2006;24:1754–1760.

75. Li Y, Zhou X, St John MA, et al. RNA profiling of cell-free saliva using microarray technology. *J Dent Res.* 2004;83:199–203.

76. Li Y, St John MA, Zhou X, et al. Salivary transcriptome diagnostics for oral cancer detection. *Clin Cancer Res.* 2004;10:8442–8450.

77. Park NJ, Zhou H, Elashoff D, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. *Clin Cancer Res.* 2009;15:5473–5477.

78. Sugimoto M,Wong DT, Hirayama A, et al. Capillary electrophoresismass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer–specific profiles. *Metabolomics.* 2010;6:78–95.

79. Farrell JJ, Zhang L, Zhou H, et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. *Gut.* 2012;61:582–588.

80. Zhang L, Farrell JJ, Zhou H, et al. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. *Gastroenterology.* 2010;138:949–957, e941–e947.

81. Lau C, Kim Y, Chia D, et al. Role of pancreatic cancer–derived exosomes in salivary biomarker development. *J Biol Chem.* 2013;288:26888–26897.

82. Kaur S, Kumar S, Momi N, et al. Mucins in pancreatic cancer and its microenvironment. *Nat Rev Gastroenterol Hepatol.* 2013;10:607–620.

83. Horn A, Chakraborty S, Dey P, et al. Immunocytochemistry for MUC4 and MUC16 is a useful adjunct in the diagnosis of pancreatic adenocarcinoma on fine-needle aspiration cytology. *Arch Pathol Lab Med.* 2013;137:546–551.

84. Carrara S, Cangi MG, Arcidiacono PG, et al.Mucin expression pattern in pancreatic diseases: findings from EUS-guided fine-needle aspiration biopsies. *Am J Gastroenterol.* 2011;106:1359–1363.

85. Jhala N, Jhala D, Vickers SM, et al. Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates. *Am J Clin Pathol.* 2006;126:572–579.

86. Baine M. Pancreatic cancer biomarkers. In: *Encyclopedia of Cancer.* Heidelberg, Germany: Springer; 2009:790–805.

87. Wang G, Lipert RJ, Jain M, et al. Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering. *Anal Chem.* 2011;83:2554–2561.

88. Pedersen JW, Blixt O, Bennett EP, et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. *Int J Cancer.* 2011;128:1860–1871.

89. Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. *Cell.* 2012;148:349–361.

90. Rhim AD, Thege FI, Santana SM, et al. Detection of circulating pancreas epithelial cells in patientswith pancreatic cystic lesions. *Gastroenterology.* 2014;146:647–651.

91. Yu J, Blackford AL, Dal Molin M, et al. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages [published online ahead of print January 30, 2015]. *Gut.* 2015.

92. Kanda M, Knight S, Topazian M, et al. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. *Gut.* 2013;62:1024–1033.

93. Kanda M, Sadakari Y, Borges M, et al. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. *Clin Gastroenterol Hepatol.* 2013;11:719–730 e715.

94. Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. *Gastroenterology.* 2012;142:796–804; quiz e714–e795.

95. Kern S, Hruban R, Hollingsworth MA, et al. Awhite paper: the product of a pancreas cancer think tank. *Cancer Res.* 2001;61:4923–4932.

96. Rulyak SJ, Kimmey MB, Veenstra DL, et al. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. *Gastrointest Endosc.* 2003;57:23–29.

97. Tio TL, Tytgat GN, Cikot RJ, et al. Ampullopancreatic carcinoma: preoperative TNM classification with endosonography. *Radiology.* 1990;175:455–461.

98. Grimm H, Maydeo A, Soehendra N. Endoluminal ultrasound for the diagnosis and staging of pancreatic cancer. *Baillieres Clin Gastroenterol.* 1990;4:869–888.

99. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. *Clin Gastroenterol Hepatol.* 2006;4:766–781 quiz 665.

100. Rajan E, Clain JE, Levy MJ, et al. Age-related changes in the pancreas identified by EUS: a prospective evaluation. *Gastrointest Endosc.* 2005;61:401–406.

101. Wallace MB, Hawes RH, Durkalski V, et al. The reliability of EUS for the diagnosis of chronic pancreatitis: interobserver agreement among experienced endosonographers. *Gastrointest Endosc.* 2001;53:294–299.

102. Wallace MB, Hawes RH. Endoscopic ultrasound in the evaluation and treatment of chronic pancreatitis. *Pancreas.* 2001;23:26–35.

103. Topazian M, Enders F, Kimmey M, et al. Interobserver agreement for EUS findings in familial pancreatic-cancer kindreds. *Gastrointest Endosc.* 2007;66:62–67.

104. Hocke M, Ignee A, Dietrich CF. Contrast-enhanced endoscopic ultrasound in the diagnosis of autoimmune pancreatitis. *Endoscopy.* 2011;43:163–165.

105. Dietrich CF, Wehrmann T, Hoffmann C, et al. Detection of the adrenal glands by endoscopic or transabdominal ultrasound. *Endoscopy.* 1997;29:859–864.

106. Saftoiu A, Vilman P. Endoscopic ultrasound elastography—a new imaging technique for the visualization of tissue elasticity distribution. *J Gastrointestin Liver Dis.* 2006;15:161–165.

107. Janssen J, Schlorer E, Greiner L. EUS elastography of the pancreas: feasibility and pattern description of the normal pancreas, chronic pancreatitis, and focal pancreatic lesions. *Gastrointest Endosc.* 2007;65:971–978.

108. Staton CA, Chetwood AS, Cameron IC, et al. The angiogenic switch occurs at the adenoma stage of the adenoma carcinoma sequence in colorectal cancer. *Gut.* 2007;56:1426–1432.

109. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. *Clin Cancer Res.* 2007;13:2870–2875.

110. Korpanty G, Carbon JG, Grayburn PA, et al. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. *Clin Cancer Res.* 2007;13:323–330.

111. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. *J Clin Oncol.* 2005;23:1011–1027.

112. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. *Cancer Res.* 2005;65:3967–3979.

113. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. *Nat Rev Cancer.* 2003;3:401–410.

114. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell.* 2000;100:57–70.

115. Spano JP, Chodkiewicz C, Maurel J, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. *Lancet.* 2008;371:2101–2108.

116. Longo R, Cacciamani F, Naso G, et al. Pancreatic cancer: from molecular signature to target therapy. *Crit Rev Oncol Hematol.* 2008;68:197–211.

117. Buchler P, Reber HA, Roth MM, et al. Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer. *Neoplasia.* 2007;9:119–127.

118. Tonra JR, Deevi DS, Corcoran E, et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. *Clin Cancer Res.* 2006;12:2197–2207.

119. Higgins KJ, Abdelrahim M, Liu S, et al. Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. *Biochem Biophys Res Commun.* 2006;345:292–301.

120. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. *Mol Cancer.* 2003;2:8.

121. Shi Q, Le X, Abbruzzese JL, et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. *Cancer Res.* 2001;61:4143–4154.

122. Luo J, Guo P, Matsuda K, et al. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. *Int J Cancer.* 2001;92:361–369.

123. Itakura J, Ishiwata T, Friess H, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. *Clin Cancer Res.* 1997;3:1309–1316.

124. Deshpande N, Ren Y, Foygel K, et al. Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging. *Radiology.* 2011;258:804–811.

125. Foygel K, Wang H, Machtaler S, et al. Detection of pancreatic ductal adenocarcinoma in mice by ultrasound imaging of thymocyte differentiation antigen 1. *Gastroenterology.* 2013;145:885–894 e883.

126. Hausner SH, Bauer N, Sutcliffe JL. In vitro and in vivo evaluation of the effects of aluminum [(1)(8)F]fluoride radiolabeling on an integrin alphavbeta(6)-specific peptide. *Nucl Med Biol.* 2014;41:43–50.

127. Hausner SH, Carpenter RD, Bauer N, et al. Evaluation of an integrin alphavbeta6–specific peptide labeled with [18F]fluorine by copper-free, strain-promoted click chemistry. *Nucl Med Biol.* 2013;40:233–239.

128. Cote GA, Smith J, Sherman S, et al. Technologies for imaging the normal and diseased pancreas. *Gastroenterology.* 2013;144:1262–1271 e1261.

129. Zhu X, Li J, Hong Y, et al. 99mTc-labeled cystine knot peptide targeting integrin alphavbeta6 for tumor SPECT imaging. *Mol Pharm.* 2014;11:1208–1217.

130. Kimura RH, Teed R, Hackel BJ, et al. Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. *Clin Cancer Res.* 2012;18:839–849.

131. Liu Z, Liu H, Ma T, et al. Integrin alphavbeta6–targeted SPECT imaging for pancreatic cancer detection. *J Nucl Med.* 2014;55:989–994.

132. Trajkovic-Arsic M, Mohajerani P, Sarantopoulos A, et al. Multimodal molecular imaging of integrin alphavbeta3 for in vivo detection of pancreatic cancer. *J Nucl Med.* 2014;55:446–451.

133. Shin SJ, Smith JA, Rezniczek GA, et al. Unexpected gain of function for the scaffolding protein plectin due to mislocalization in pancreatic cancer. *Proc Natl Acad Sci U S A.* 2013;110:19414–19419.

134. Kelly KA, Bardeesy N, Anbazhagan R, et al. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. *PLoS Med.* 2008;5:e85.

135. Bausch D, Thomas S, Mino-Kenudson M, et al. Plectin-1 as a novel biomarker for pancreatic cancer. *Clin Cancer Res.* 2011;17:302–309.

136. Nimmagadda S, Pullambhatla M, Lisok A, et al. Imaging Axl expression in pancreatic and prostate cancer xenografts. *Biochem Biophys Res Commun.* 2014;443:635–640.

137. Montet X, Weissleder R, Josephson L. Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas. *Bioconjug Chem.* 2006;17:905–911.

138. Petersen GM, de Andrade M, Goggins M, et al. Pancreatic cancer genetic epidemiology consortium. *Cancer Epidemiol Biomarkers Prev.* 2006;15:704–710.

139. Sherman S, Shats O, Ketcham MA, et al. PCCR: Pancreatic Cancer Collaborative Registry. *Cancer Inform.* 2011;10:83–91.

140. Ruiz C, Lenkiewicz E, Evers L, et al. Advancing a clinically relevant perspective of the clonal nature of cancer. *Proc Natl Acad Sci U S A.* 2011;108:12054–12059.

141. Remmers N, Anderson JM, Linde EM, et al. Aberrant expression of mucin core proteins and *o*-linked glycans associated with progression of pancreatic cancer. *Clin Cancer Res.* 2013;19:

1981–1993.

142. Ingkakul T, Sadakari Y, Ienaga J, et al. Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas. *Ann Surg.* 2010;

251:70–75.

143. Feng Z, Kagan J, Pepe M, et al. The Early Detection Research Network's specimen reference sets: paving the way for rapid evaluation of potential biomarkers. *Clin Chem.* 2013;59:68–74.